

Special Issue

Advancement in Design and Synthesis of Novel Drug

Message from the Guest Editor

The development of a novel medicine starts when researchers learn of a biological target, such as protein, gene, receptor etc., which plays a critical role in diseases such as cancers, diabetes, or neurological disorders. This Special Issue will cover the discovery and development of a variety of novel agents. Here, we will cover the discovery and development of entirely new agents, those with a mode of action different from already approved medicines and intended for clinical translations. Our aim is to publish the recent advancement in the area of drug discovery and development. One overall theme of our Special Issue is to report the preclinical or clinical studies of novel agents and understand their designing, synthesis, and characterization. This Special Issue will facilitate the translation of new agents to the next level. As editors of the journal, we encourage the submission of research reports that provide data relevant to this Special Issue.


Guest Editor

Dr. Manoj K. Pandey

Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA

Deadline for manuscript submissions

closed (30 November 2021)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/48349

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).